Healthcare
Alpha Teknova, Inc.(TKNO)
Live Price
Offline$5.24
+5.86% today
1Y Change
-17.09%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $180.00M
- Revenue Growth
- +7.4%
- EPS Growth
- +43.9%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alpha Teknova, Inc. (TKNO) is a Healthcare stock with a market cap of $180.00M and listed on NASDAQ. The stock last traded around $5.24 and down 17.1% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +7.4%, EPS growth of +43.9%, a dividend yield of 0.0%. What stands out right now is revenue +7.4%, EPS +43.9%, free cash flow +31.7% with operating margin -41.9% and ROIC -17.3%. Valuation sits in the middle of the pack at price/sales 4.5. Stock Foundry combines TKNO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.4% vs +7.6% peer median
Operating Margin
Below sector median
-41.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +7.4% and EPS at +43.9%, with operating margin around -41.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -5.6% | +4.0% | +12.9% |
2026 Feb 26, 2026 | +0.0% | +13.2% | -3.1% | +24.1% |
2025 Nov 6, 2025 | +14.8% | -2.1% | -7.9% | -0.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TKNO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TKNO Max Drawdown
-68.76%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TKNO and SPY.
Company Overview
Alpha Teknova, Inc.
NASDAQ Global Market
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
- Leadership
- Stephen Gunstream
- IPO Date
- Jun 25, 2021
- Employees
- 173
- Street Address
- 2290 Bert Drive
- Mailing
- Hollister, CA, 95023
- Region
- Hollister, CA, US
- Reporting Currency
- USD
- Investor Line
- 831 637 1100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.5
- Price/Book
- 2.6
Growth
- Revenue
- +7.4%
- EPS
- +43.9%
- Free Cash Flow
- +31.7%
Profitability
- Gross Margin
- 33.2%
- Operating Margin
- -41.9%
- Net Margin
- -42.6%
- ROE
- -23.3%
- ROIC
- -17.3%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 4.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.